EP Patent

EP4161487A2 — Novel pharmaceutical composition comprising combination of olopatadine and nepafenac

Assigned to Zenvision Pharma LLP · Expires 2023-04-12 · 3y expired

What this patent protects

The present invention relates to a novel pharmaceutical composition comprising combination of Olopatadine or salt thereof and Nepafenac or salt thereof, process for preparation thereof and use thereof for the treatment of ophthalmic disorders.

USPTO Abstract

The present invention relates to a novel pharmaceutical composition comprising combination of Olopatadine or salt thereof and Nepafenac or salt thereof, process for preparation thereof and use thereof for the treatment of ophthalmic disorders.

Drugs covered by this patent

chloroprocaine-hydrochloride (CHLOROPROCAINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP4161487A2
Jurisdiction: EP
Classification: —
Expires: 2023-04-12
Drug substance claim: No
Drug product claim: No
Assignee: Zenvision Pharma LLP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.